Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renske van der Meer

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Respiration; International Review of Thoracic Diseases|March 12, 2024
Treatable Traits in Pregnant Women with AsthmaMeera Ramlal, Renske Van der Meer, Sarah Bendien
Journal of Personalized Medicine|June 2, 2021
CFTR Modulators: Does One Dose Fit All?Renske van der Meer, Erik B Wilms, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|September 11, 2019
Prevention of drug-related complications in cystic fibrosisRenske van der Meer, Daan J Touw, Harry G M Heijerman
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 19, 2021
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controlsRenske van der Meer, Erik B Wilms, Richart Sturm, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 11, 2025
Adverse events to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: A case seriesSyendon B C Baromeo, Renske van der Meer, Richard C J M van Rossen, et al.
Therapeutic Drug Monitoring|February 13, 2020
Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?Erik M van Maarseveen, Renske van der Meer, Cees Neef, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 27, 2021
Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?Joshena Jeyaratnam, Renske van der Meer, Gitte Berkers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 10, 2022
The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosisRenske van der Meer, Erik B Wilms, Margot N Eggermont, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 30, 2024
Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction studyRenske van der Meer, Erik B Wilms, Margot N Eggermont, et al.
Medical Mycology|March 6, 2024
Evaluation of the drug-drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohortAnouk M E Jansen, Margot N Eggermont, Erik B Wilms, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Respiration; International Review of Thoracic Diseases|March 12, 2024
Treatable Traits in Pregnant Women with AsthmaMeera Ramlal, Renske Van der Meer, Sarah Bendien
Journal of Personalized Medicine|June 2, 2021
CFTR Modulators: Does One Dose Fit All?Renske van der Meer, Erik B Wilms, Harry G M Heijerman
Current Opinion in Pulmonary Medicine|September 11, 2019
Prevention of drug-related complications in cystic fibrosisRenske van der Meer, Daan J Touw, Harry G M Heijerman
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 19, 2021
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controlsRenske van der Meer, Erik B Wilms, Richart Sturm, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 11, 2025
Adverse events to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: A case seriesSyendon B C Baromeo, Renske van der Meer, Richard C J M van Rossen, et al.
Therapeutic Drug Monitoring|February 13, 2020
Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?Erik M van Maarseveen, Renske van der Meer, Cees Neef, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 27, 2021
Breast development in a 7 year old girl with CF treated with ivacaftor: An indication for personalized dosing?Joshena Jeyaratnam, Renske van der Meer, Gitte Berkers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 10, 2022
The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosisRenske van der Meer, Erik B Wilms, Margot N Eggermont, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 30, 2024
Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction studyRenske van der Meer, Erik B Wilms, Margot N Eggermont, et al.
Medical Mycology|March 6, 2024
Evaluation of the drug-drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohortAnouk M E Jansen, Margot N Eggermont, Erik B Wilms, et al.
Pageof 3